KRTX - Karuna Therapeutics GAAP EPS of -$2.38 misses by $0.27

• Karuna Therapeutics press release ( NASDAQ: KRTX ): Q3 GAAP EPS of -$2.38 misses by $0.27 .
• The Company ended the quarter with $1.2 billion in cash, cash equivalents and available-for-sale investment securities compared to $494.0 million as of December 31, 2021. The increase was primarily the result of the completion of the Company’s public offering in August 2022, which resulted in net proceeds of $819.1 million. The Company expects that current cash, cash equivalents and available-for-sale investment securities as of September 30, 2022, will enable to Company to fund operating expenses and capital expenditure requirements through the end of 2025.

For further details see: